ANGO
AngioDynamics reports in-line; guides above consensus (ANGO) : Reports Q3 (Feb) earnings of $0.14 per share, in-line with the Reuters Estimates consensus of $0.14; revenues rose 28.2% year/year to $19.8 mln vs the $20 mln consensus. Co raises guidance for FY06, to EPS of $0.57 from $0.52 vs. $0.55 consensus; sees FY06 revs of "at least" $78 up from at least $76 mln mln vs. $77.88 mln consensus.
ANGO AngioDynamics tgt raised to $33 from $27 at RBC following Q3 in-line results and Q4 upside guidance
THE CHAP STOCKS
NABI
NABI Biopharma announces development of StaphVAX and Altastaph to Continue (NABI) 4.80 -0.16: Co announces it will continue development of its Gram-positive program, led by StaphVAX and Altastaph. Today's decision was based on important conclusions from an outside advisory panel's review of the co's assessment of the StaphVAX confirmatory Phase III clinical study results. The assessment revealed marked differences in the effectiveness of the lot of vaccine used in this study compared to the lot used in the previous Phase III clinical study
AngioDynamics reports in-line; guides above consensus (ANGO) : Reports Q3 (Feb) earnings of $0.14 per share, in-line with the Reuters Estimates consensus of $0.14; revenues rose 28.2% year/year to $19.8 mln vs the $20 mln consensus. Co raises guidance for FY06, to EPS of $0.57 from $0.52 vs. $0.55 consensus; sees FY06 revs of "at least" $78 up from at least $76 mln mln vs. $77.88 mln consensus.
ANGO AngioDynamics tgt raised to $33 from $27 at RBC following Q3 in-line results and Q4 upside guidance
THE CHAP STOCKS
NABI
NABI Biopharma announces development of StaphVAX and Altastaph to Continue (NABI) 4.80 -0.16: Co announces it will continue development of its Gram-positive program, led by StaphVAX and Altastaph. Today's decision was based on important conclusions from an outside advisory panel's review of the co's assessment of the StaphVAX confirmatory Phase III clinical study results. The assessment revealed marked differences in the effectiveness of the lot of vaccine used in this study compared to the lot used in the previous Phase III clinical study
